Avalo Therapeutics, Inc. AVTX

AVTX Company Overview

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company operates within the biotechnology and biopharmaceutical industries, with an emphasis on immunology and inflammation-related indications. Avalo’s strategy centers on advancing targeted biologic therapies intended to address diseases with significant unmet medical need, particularly in areas where existing treatment options are limited or insufficiently effective.

The company’s primary value driver is its clinical-stage pipeline, led by investigational monoclonal antibody programs targeting inflammatory pathways. Avalo evolved through a series of corporate restructurings and strategic pivots, including its transition from earlier operations under the Cerecor name into a more focused immunology-oriented biotechnology platform. Public filings and investor communications indicate that the company has narrowed its operational focus toward selective immunology assets and capital-efficient clinical development.